Rajat Bannerji, MD, PhD

Articles by Rajat Bannerji, MD, PhD

Dr. Bannerji on the Toxicity Profile of Odronextamab in Non-Hodgkin Lymphoma

ByRajat Bannerji, MD, PhD

January 6th 2021

Rajat Bannerji, MD, PhD, discusses the toxicity profile of odronextamab in non-Hodgkin lymphoma.

Dr. Bannerji on Ongoing Research With REGN1979 in Non-Hodgkin Lymphoma

ByRajat Bannerji, MD, PhD

April 22nd 2020

Rajat Bannerji, MD, PhD, hematologist/oncologist and chief of hematologic malignancies at the Rutgers Cancer Institute of New Jersey, discusses ongoing research with the bispecific antibody REGN1979 in non-Hodgkin lymphoma (NHL).

Dr. Bannerji on the Clinical Activity of the Bispecific Antibody REGN1979 in NHL

ByRajat Bannerji, MD, PhD

January 30th 2020

Rajat Bannerji, MD, PhD, hematologist/oncologist and chief of hematologic malignancies at the Rutgers Cancer Institute of New Jersey, discusses the clinical activity of the bispecific antibody REGN1979 in patients with non-Hodgkin lymphoma (NHL).